Vanda Pharmaceuticals (VNDA) Earns Media Sentiment Rating of 0.20

News articles about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.7865140068549 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several equities research analysts have issued reports on the stock. Oppenheimer reiterated a “buy” rating and issued a $25.00 price target on shares of Vanda Pharmaceuticals in a research note on Sunday, November 12th. ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Finally, Piper Jaffray Companies set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Vanda Pharmaceuticals currently has an average rating of “Buy” and an average price target of $21.50.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down $0.25 during mid-day trading on Wednesday, reaching $13.60. 488,500 shares of the company’s stock traded hands, compared to its average volume of 548,537. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. During the same quarter last year, the firm posted ($0.01) EPS. The company’s quarterly revenue was up 7.3% on a year-over-year basis. equities research analysts anticipate that Vanda Pharmaceuticals will post -0.42 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply